Document is current

Article History

Accepted: 30 July 2024

First Online: 9 September 2024

Competing interests

: G.C. has received consulting and speaking fees from Bristol Myers, Janssen, Novartis, Rewind, Roche, Sanofi and Squibb. G.D.C. has received funding for research, travel and/or speaker honoraria from Biogen, Celgene, Merck, Novartis, Roche and Teva. B.S. has received research support from Merck, Novartis and Roche and honoraria for lectures from Biogen, Janssen, Novartis, Merck and Sanofi. H.-P.H. received honoraria for serving on steering committees from Roche, Sanofi and TG Therapeutics, for serving on data monitoring committees from Merck KG and Novartis and on the scientific advisory board of Aurinia. P.S.S. has received personal compensation for serving on scientific advisory boards, steering committees or independent data monitoring boards for Biogen, Celgene, Forward Pharma GlaxoSmithKline, Genzyme, MedDay Pharmaceuticals, Merck, Novartis and TEVA and has received speaker honoraria from Biogen, Genzyme Merck, Novartis and Teva. His department has received research support from Biogen, Merck, Novartis, Roche, RoFAR, Sanofi-Aventis/Genzyme and TEVA. P.V. has received honorarium for contribution to meetings from AB Science, Ad Scientiam, Biogen, BMS-Celgene, Imcyse, Janssen, Merck, Novartis, Roche, Sanofi-Genzyme and Teva and research support from Merck, Novartis and Sanofi-Genzyme. L.L. has received research support from Almirall, Biogen, Merck and Novartis and consultancy or speaker fees from Almirall, Biogen, Bristol-Myers Squibb, Janssen-Cilag, Merck, Novartis and Roche.